智通财经APP讯，医渡科技(02158)公布，2026年1月29日耗资约72.82万港元回购12.18万股股份。 ...

格隆汇1月29日丨医渡科技(02158.HK)公告，1月29日耗资72.8万港元回购12.2万股。 ...

Core Viewpoint - Jiang Jiangyu has resigned as a non-executive director of Jin Hai Medical Technology, effective January 29, 2026, to focus more on his other business ventures [1] Group 1 - Jiang Jiangyu will also cease to serve as the vice chairman of the board following his resignation [1]

Group 1 - The Shandong Provincial Government is focusing on the development of key industries, including new generation information technology and artificial intelligence, as well as emerging sectors like life health and green energy, as part of its "10+1" industrial development strategy [2] - Qingdao University is aligning its academic programs with the regional industrial layout by establishing interdisciplinary doctoral programs in areas such as low-altitude technology and artificial intelligence [2][3] - The university has formed seven academic clusters from 39 disciplines, emphasizing peak disciplines in systems, textiles, and medicine, while also developing advantageous clusters in new energy and cultural creativity [3] Group 2 - Qingdao University has established its own medical technology company to leverage its clinical advantages, focusing on smart medical devices and innovative healthcare solutions [4] - The university is actively promoting the construction of research centers in extreme environment medicine and artificial intelligence, with several projects already approved or in progress [3] - The integration of AI into various research initiatives is a priority for Qingdao University, aiming to enhance its contributions to the local economy and healthcare innovation [2][4]

Group 1 - The Shandong Provincial People's Congress emphasized the importance of a first-class university named after a city as a hallmark of a modern international metropolis, with a focus on high-quality development of local universities and application-oriented institutions [1] - Qingdao University aims to leverage its strengths in medicine, healthcare, and engineering to contribute to the development of the Qingdao Science and Technology Innovation Corridor and the "China Health Bay" initiative, presenting both challenges and opportunities for the institution [1] Group 2 - Qingdao City has outlined a "10+1" industrial development strategy focusing on emerging industries such as new generation information technology, artificial intelligence, and health, while also enhancing existing industries like smart home appliances and high-end chemicals [2] - Qingdao University has established eight interdisciplinary doctoral programs in areas such as low-altitude technology and artificial intelligence, fostering a collaborative ecosystem through the integration of education and industry [2] Group 3 - Qingdao University has organized 39 first-level disciplines into seven discipline clusters, with a focus on developing peak discipline clusters in "system+", "textile+", and "medicine+" [3] - The university is actively promoting projects related to extreme environment special medicine and artificial intelligence, with plans for future energy and intelligent connected vehicle centers [3] Group 4 - Qingdao University has established its own wholly-owned medical technology company to incubate innovations in smart diagnostics, medical devices, and pharmaceuticals, aiming to create a strong brand in medical technology [4]

Core Insights - Strive has increased its Bitcoin holdings to over $1.1 billion, positioning itself among the top 10 publicly traded holders of Bitcoin [1] - The firm acquired 333.89 Bitcoin at an average price of $89,851, raising its total Bitcoin holdings to 13,131.82 BTC [2] - Strive has paid off 92% of the debt from its acquisition of Semler Scientific, a medical technology firm that adopted a Bitcoin treasury strategy [2][3] Company Actions - Strive's CEO, Matt Cole, highlighted the company's effective management of a Bitcoin-powered treasury and plans to retire the remaining debt by April [3] - The firm has reverted to a preferred equity-only amplification structure to align Bitcoin financing with its long-duration nature [4] - Strive completed a follow-on offering of 1.3 million shares of its preferred stock SATA at $90 per share, with over $600 million in demand [6] Acquisition Details - The acquisition of Semler Scientific was approved by shareholders two weeks prior, combining Semler's 5,048 BTC with Strive's holdings [5] - The deal was finalized shortly after the approval, impacting the share prices of both companies [5] Market Performance - Strive's shares (ASST) have decreased approximately 1.5% since the announcement and nearly 10% over the week, with a significant drop of over 78% in the last six months [7]

Group 1 - The stock price of Saily Medical (603716) closed at 23.29 yuan on January 28, 2026, down 4.71%, with a turnover rate of 7.5%, trading volume of 157,600 shares, and a transaction amount of 374 million yuan [1] - On January 28, 2026, there was a net outflow of 37.966 million yuan from institutional investors and 33.4873 million yuan from retail investors, while retail investors had a net inflow of 71.4533 million yuan [1][4] - A block trade occurred on January 28, 2026, with a transaction amount of 22 million yuan [2] Group 2 - Saily Medical announced that its major shareholder, Shanghai Angze Private Fund Management Co., Ltd., reduced its holdings by a total of 1.5 million shares from December 12, 2025, to January 28, 2026, accounting for 0.7137% of the company's total share capital, during which the stock price increased by 12.4% [3] - The total reduction by Shanghai Angze Private Fund amounted to 3,091,200 shares, representing 1.47% of the total share capital, with a reduction price range of 19.64 to 22.00 yuan per share, totaling 65.226349 million yuan [3][4] - After the reduction, Shanghai Angze held 9,009,199 shares, accounting for 4.29% of the total share capital, and is no longer classified as a major shareholder [3][4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300109 证券简称：新开源 公告编号：2026-016 博爱新开源医疗科技集团股份有限公司 关于回购部分股份用于注销并减少注册资本暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、通知债权人的原因 博爱新开源医疗科技集团股份有限公司（以下简称 "公司"）于2026年1月7日召开的第五届董事会第二 十一次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，该议案已经2026年1 月27日召开的2026年第二次临时股东大会审议通过，详见公司于2026年1月27日在中国证监会指定创业 板信息披露网站上披露的相关公告。 根据回购方案，公司拟使用资金总额不低于人民币4,000万元（含本数），且不超过人民币5,000万元 （含本数）的自有资金，以不超过人民币25.77元/股的回购价格，以集中竞价交易方式通过二级市场回 购部分公司A股社会公众股份。本次回购股份的用途为：依法予以注销并相应减少注册资本。本次回购 股份的实施期限为公司股东大会审议通过本回购股份方案之日起6个月内。 ...

Core Insights - The article highlights the significance of the Boao Lecheng International Medical Tourism Pilot Zone as China's only "medical special zone," serving as a key window for high-level openness and quality development of Hainan Free Trade Port [1] Group 1: Medical Tourism Growth - In the past year, medical tourism in Lecheng surpassed 860,000 visits, marking a year-on-year increase of 109% [1] - Medical revenue exceeded 8.39 billion yuan, reflecting a year-on-year growth of 51.5% [1] - Over 9,300 international patients from 14 countries and regions visited Lecheng, with a sixfold increase in numbers post-border reopening, indicating a trend of seeking medical treatment in China [1] Group 2: Innovation in Medical Technology - Lecheng introduced over 100 types of global innovative drugs, medical devices, special medical foods, and health products last year [1] - Notable advancements include the introduction of China's first boron neutron capture therapy system, which targets tumor cells precisely without harming healthy tissue, offering new hope for cancer patients [1] Group 3: Future Aspirations - By 2025, Lecheng aims to become a world-class medical tourism destination and a platform for medical technology innovation, facilitating domestic patients to receive care without going abroad and attracting international visitors for health services [1]

Core Insights - Alibaba Health's medical AI application "Hydrogen Ion" has launched a key version update featuring a new function called "Dynamic Evidence Localization" which allows precise identification of specific statements supporting claims, while also verifying their timeliness, authority, and logical consistency [2] Group 1: Dynamic Evidence Localization - The new function upgrades traditional "static citation" methods to "living evidence," addressing the industry's challenge of determining whether information is still valid and credible [2] - The system integrates timeliness and authority into its citation logic, continuously updating and filtering global guidelines and literature to ensure responses are based on the latest and most reliable medical evidence [2][3] Group 2: User Experience and Impact - When users inquire about specific clinical trial data, the system provides structured medical conclusions with citation tags, allowing seamless tracing back to original literature and supporting statements [3] - This technology significantly reduces the information verification cost for clinical and research work, enabling doctors to make decisions without pausing to check original documents, as the AI performs triple verification of effectiveness, authority, and logical consistency [3]